Global Vulvovaginal Candidiasis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Vulvovaginal Candidiasis Treatment Market is presumed to reach the market size of nearly USD 6.96 BN by 2030 from USD 4.2 BN in 2022 with a CAGR of 6.51% under the study period 2023 - 2030.

Vulvovaginal candidiasis treatment is a treatment for vaginal yeast infection, a common fungus infection. Itching, a burning feeling or discomfort during urine or intercourse, swelling, rash, and inflammation, are all signs of vaginal yeast infection. As diabetic cases rise and people use antibiotics more frequently, vulvovaginal candidiasis prevalence has grown. Antifungal medicines are typically recommended for the treatment of vaginal candidiasis.

MARKET DYNAMICS:

The market is foreseen to follow a growing trend with the increase in vulvovaginal candidiasis infections and the requirement for effective medicines to treat the condition. The significant increase in research and development, new drug approvals, and product launches are scaling up the demand for better treatment options, creating a profitable opportunity for the commercial growth of vulvovaginal candidiasis treatment. In addition, there will be a lot of opportunities for the treatment of vulvovaginal candidiasis over the anticipated time frame because of an increase in healthcare and government investments, development of the healthcare system, accessibility of medications, and significant technological developments in the pharmaceutical and biotechnology sectors. The market for vulvovaginal candidiasis treatment is estimated to be hampered due to lack of public awareness, expertise in employing new technologies, and high costs related to diagnostic and treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vulvovaginal candidiasis treatment. The growth and trends of vulvovaginal candidiasis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the vulvovaginal candidiasis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others

By Route Of Administration

Oral
Intravenous
Topical

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Vulvovaginal Candidiasis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the vulvovaginal candidiasis treatment market include Astellas Pharma Inc., Mycovia Pharmaceuticals Inc., Bayer AG., Basilea Pharmaceutica Ltd., Scynexis Inc., Grupo Ferrer Internacional S.A., Pfizer Inc., Cadila Pharmaceuticals, Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219892

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . VULVOVAGINAL CANDIDIASIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Clotrimazole Historic and Forecast Sales by Regions
6.5 Nystatin Historic and Forecast Sales by Regions
6.6 Fluconazole Historic and Forecast Sales by Regions
6.7 Ketoconazole Historic and Forecast Sales by Regions
6.8 Terbinafine Historic and Forecast Sales by Regions
6.9 Terconazole Historic and Forecast Sales by Regions
6.10. Others Historic and Forecast Sales by Regions

7 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Intravenous Historic and Forecast Sales by Regions
7.6 Topical Historic and Forecast Sales by Regions

8 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacy Historic and Forecast Sales by Regions
8.5 Retail Pharmacy Historic and Forecast Sales by Regions
8.6 Online Pharmacy Historic and Forecast Sales by Regions

9 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VULVOVAGINAL CANDIDIASIS TREATMENT COMPANIES

10.1. Vulvovaginal Candidiasis Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF VULVOVAGINAL CANDIDIASIS TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Astellas Pharma Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Mycovia Pharmaceuticals Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Bayer AG.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Basilea Pharmaceutica Ltd.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Scynexis Inc.
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Grupo Ferrer Internacional S.A.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Pfizer Inc.
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Cadila Pharmaceuticals
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Bristol-Myers Squibb Company
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies